Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder

Abstract

Objective Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD). Method Treatment-resistant depression was defined as a documented history of current-episode antidepressant failure plus a prospective failure on fluoxetine. Following an 8-week fluoxetine lead-in, 605 nonresponders with DSM-IV major depressive disorder were randomly assigned to olanzapine/fluoxetine combination, olanzapine, or fluoxetine. The primary outcome measure was baseline-to-endpoint mean change on the Montgomery-Asberg Depression Rating Scale (MADRS). The study was conducted from April 2002 to May 2005. Results After 8 weeks of double-blind treatment, Study 1 revealed no statistically significant therapy differences in MADRS mean change (olanzapine/fluoxetine combination: -11.0, fluoxetine: -9.4, olanzapine: -10.5). In Study 2, olanzapine/fluoxetine combination demonstrated significantly greater MADRS improvement (-14.5) than fluoxetine (-8.6, p Conclusion Patients with TRD (defined as treatment failure on 2 antidepressants) taking olanzapine/fluoxetine combination demonstrated significantly greater improvement in depressive symptoms than patients taking olanzapine or fluoxetine in 1 of 2 studies and in the pooled analysis. When considered within the context of all available evidence, olanzapine/fluoxetine combination is an efficacious therapy for patients with TRD. Clinical trials registr…

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v68n0207

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 228

Metadata

Authors
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S.
Affiliations
University of Pittsburgh (US)
Venue
The Journal of Clinical Psychiatry
Published
2007-02-15
Volume
68
Issue
02
Pages
224-236
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2125094332
Cited by
228
References
0
Citations by year
2026: 6 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 9 · 2018: 4 · 2017: 8 · 2016: 9 · 2015: 13 · 2014: 15 · 2013: 24 · 2012: 8
FWCI
18.71
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
treatment-resistant depression, major depressive disorder, olanzapine, fluoxetine, olanzapine-fluoxetine combination, atypical antipsychotics, antidepressant non-response, remission rate, cholesterol, weight gain, hyperglycemia, adverse events, outpatients, Montgomery-Asberg Depression Rating Scale, antidepressant efficacy comparison, antipsychotic augmentation, adjunctive therapy
MeSH terms
Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Middle Aged, Antipsychotic Agents, Treatment Failure, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. https://app.cochat.ai/papers/10.4088/jcp.v68n0207
The paper
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007). A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n0207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.